Aerovate Therapeutics, Inc.

NasdaqGM:AVTE Stock Report

Market Cap: US$77.7m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Aerovate Therapeutics Future Growth

Future criteria checks 0/6

Aerovate Therapeutics is forecast to grow earnings at 18.7% per annum. EPS is expected to grow by 19.5% per annum.

Key information

18.7%

Earnings growth rate

19.49%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated28 Mar 2025

Recent future growth updates

Recent updates

Analysis Article • Oct 01

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 11

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension. AV-101 can become standard of care for PAH, when added to background therapy for PAH patients, if it can be shown to be superior to Merck's Winrevair. Read the full article on Seeking Alpha
Analysis Article • May 24

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 09

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 17

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 04

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 28

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Aerovate Therapeutics...
Analysis Article • Jan 06

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Key Insights Aerovate Therapeutics' estimated fair value is US$27.2 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Oct 14

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 01

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 22

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 30

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqGM:AVTE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-21N/AN/A1
12/31/2026N/A-14N/AN/A2
12/31/2025N/A-24N/AN/A3
3/31/2025N/A-49-50-50N/A
12/31/2024N/A-70-71-71N/A
9/30/2024N/A-85-75-75N/A
6/30/2024N/A-88-75-75N/A
3/31/2024N/A-82-69-69N/A
12/31/2023N/A-76-57-57N/A
9/30/2023N/A-70-57-57N/A
6/30/2023N/A-64-51-51N/A
3/31/2023N/A-57-45-45N/A
12/31/2022N/A-52-39-39N/A
9/30/2022N/A-45-38-37N/A
6/30/2022N/A-37-34-34N/A
3/31/2022N/A-31-29-29N/A
12/31/2021N/A-23-28-27N/A
9/30/2021N/A-18-17-17N/A
6/30/2021N/A-15-13-13N/A
3/31/2021N/A-11-10-10N/A
12/31/2020N/A-10-8-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AVTE's revenue is forecast to grow faster than the US market.

High Growth Revenue: AVTE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AVTE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/29 23:38
End of Day Share Price 2025/04/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aerovate Therapeutics, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vasiliana MoussatosWedbush Securities Inc.
Laura ChicoWedbush Securities Inc.